WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Commended For Leadership In Addressing Climate Change 22 September 2010
Pfizer to Acquire FoldRx Pharmaceuticals 02 September 2010
World Health Organization Grants Prequalification to Prevenar 13 24 August 2010
Pfizer Reports Second-Quarter 2010 Results 11 August 2010
Pfizer to Offer Free Public Access to Mental Health Assessment Tools 23 July 2010
Pfizer Strengthens Manufacturing Capabilities in Asia 13 July 2010
Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program 25 June 2010
Phase 3 Study Showed MACUGENĀ® Improved Vision Over Standard of Care 07 June 2010
Pfizer Global Manufacturing Announces Plans to Reconfigure its Global Plant Network 20 May 2010
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery 26 April 2010
Pfizer Discontinues Phase 3 Trial of SutentĀ® in Advanced Hepatocellular Carcinoma 23 April 2010
Stemgent and Pfizer Announce Collaboration 16 April 2010
Pfizer Posts Details About Interactions With U.S. Physicians 01 April 2010
Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World's Poorest Countries 24 March 2010
Pfizer Discontinues A Phase 3 Study Of Figitumumab 12 March 2010
Pfizer and Medivation Announce Results From Two Phase 3 Studies in Dimebon 04 March 2010
Pfizer's Prevnar 13 Recommended by CDC's Advisory Committee On Immunization Practices 25 February 2010
Lilly, Merck, And Pfizer Announce the Formation of the Asian Cancer Research Group, Inc. 24 February 2010
Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness 09 February 2010
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results 04 February 2010
  • Start
  • Prev
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • End

Business & Industry

  • Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
  • Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
  • Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare

Research & Development

  • COVAX announces new agreement, plans for first deliveries
  • Obesity, impaired metabolic health and COVID-19
  • COVID-19 has multiple faces
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes
  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer completes acquisition of Therachon

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.